Salix Pharmaceuticals 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) July 25, 2012
SALIX PHARMACEUTICALS, LTD.
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation)
Registrant's telephone number, including area code (919) 862-1000
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
On July 25, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing it will report second quarter 2012 financial results following the close of the U.S. financial markets on Wednesday, August 8, 2012. A copy of the press release is attached hereto as Exhibit 99.1.
On July 27, 2012, Salix Pharmaceuticals, Ltd. issued a press release announcing Salix and Progenics Pharmaceuticals received a complete response letter from the U.S. Food and Drug Administration for its Supplement New Drug Application for RELISTOR® (methylnaltrexone bromide) injection for subcutaneous use for the treatment of opioid-induced constipation in adult patients with chronic, non-cancer pain. A copy of the press release is attached as Exhibit 99.2.
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.